行情

FLXN

FLXN

Flexion
NASDAQ

实时行情|Nasdaq Last Sale

19.53
+0.54
+2.84%
盘后: 19.65 +0.12 +0.61% 17:53 12/06 EST
开盘
19.11
昨收
18.99
最高
19.57
最低
18.84
成交量
144.92万
成交额
--
52周最高
19.69
52周最低
8.76
市值
7.46亿
市盈率(TTM)
-4.7316
分时
5日
1月
3月
1年
5年

分析师评级

9位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

FLXN 新闻

  • Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • GlobeNewswire.5小时前
  • The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes Dividend
  • Benzinga.14小时前
  • Stocks That Hit 52-Week Highs On Thursday
  • Benzinga.1天前
  • Benzinga's Top Upgrades, Downgrades For December 5, 2019
  • Benzinga.1天前

更多

所属板块

生物技术和医学研究
+1.28%
制药与医学研究
+0.68%

热门股票

名称
价格
涨跌幅

FLXN 简况

Flexion Therapeutics, Inc. is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company's lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid. The Company is developing Zilretta as a treatment for patients with moderate to severe OA knee pain. The Company has specifically designed Zilretta to combine a steroid, triamcinolone acetonide (TCA) with poly lactic-co-glycolic acid (PLGA), for providing sustained therapeutic concentrations in the joint and persistent analgesic effect. The Company's other product candidates include FX007 for post-operative pain and FX005 for the treatment of end-stage OA patients. The Company is engaged in conducting a Phase IIb clinical trial of Zilretta.
展开

Webull提供Flexion Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。